(NASDAQ: PRAX) Praxis Precision Medicines's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Praxis Precision Medicines's revenue in 2026 is $0.On average, 21 Wall Street analysts forecast PRAX's revenue for 2026 to be $25,594,085, with the lowest PRAX revenue forecast at $0, and the highest PRAX revenue forecast at $202,280,313. On average, 20 Wall Street analysts forecast PRAX's revenue for 2027 to be $9,840,678,970, with the lowest PRAX revenue forecast at $3,836,764,751, and the highest PRAX revenue forecast at $19,770,701,903.
In 2028, PRAX is forecast to generate $31,577,506,428 in revenue, with the lowest revenue forecast at $14,135,889,924 and the highest revenue forecast at $62,819,973,000.